Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib

Camillo Porta, Chiara Paglino

Research output: Contribution to journalArticlepeer-review


Even though Sorafenib has radically changed the natural history of those hepatocellular carcinoma patients who are not amenable for curative treatments, further therapeutic improvements are badly needed. As it was for Sorafenib, our increasingly refined understanding of the complex mechanisms underlying HCC carcinogenesis are the starting point for the future development of such treatments. Presently, a number of molecularly targeted agents are in different stages of development for this once orphan cancer. Indeed, several pathways are presently being explored to identify potentially active drugs, including epidermal growth factor receptor, vascular endothelial growth factor/vascular endothelial growth factor receptors, mammalian target of rapamycin, phosphatidyl-inositol- 3-kinase/Akt, insulin growth factor, Aurora kinase, Wnt/b-catenin, retinoic acid receptor and hepatocyte growth factor/C-Met. This review is aimed at addressing the results obtained so far with these newer drugs, also considering the challenges we shall face in the near future, including the issue of response evaluation and identification of predictive/ prognostic biomarkers.

Original languageEnglish
Pages (from-to)103-113
Number of pages11
JournalWorld Journal of Hepatology
Issue number3
Publication statusPublished - 2010

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib'. Together they form a unique fingerprint.

Cite this